The Transcriptional Landscape of Atrial Fibrillation: A Systematic Review and Meta-analysis

SUMMARY

Background Despite advances in understanding atrial fibrillation (AF) pathophysiology, there is limited agreement on the key genes driving its pathophysiology. To understand the genome-wide transcriptomic landscape, we performed a meta-analysis from studies reporting gene expression patterns in atrial heart tissue from patients with AF and controls in sinus rhythm (SR).

Methods Bibliographic databases and data repositories were systematically searched for studies reporting gene expression patterns in atrial heart auricle tissue from patients with AF and controls in sinus rhythm. We calculated the pooled differences in individual gene expression from fourteen studies comprising 534 samples (353 AF and 181 SR) to create a consensus signature (CS), from which we identified differentially regulated pathways, estimated transcription factor activity, and evaluated its performance in classifying validation samples as AF or SR.

Results Despite heterogeneity in the top differentially expressed genes across studies, the AF-CS in both chambers were robust, showing a better performance in classifying AF status than individual study signatures. Functional analysis revealed commonality in the dysregulated cellular processes between chambers, including extracellular matrix remodeling, cardiac conduction, metabolic derangements, and innate immune system activity. Finally, the AF-CS showed a good performance differentiating AF from controls in three validation datasets (two from peripheral blood and one from left ventricle samples).

Conclusions Despite variability in individual studies, this meta-analysis elucidated conserved molecular pathways involved in AF pathophysiology across its phenotypes and the potential of a transcriptomic signature in identifying AF from peripheral blood samples. Our work highlights the value of integrating published transcriptomics data in AF and the need for better data deposition practices.

• Download figure
• Open in new tab

Graphical abstract

What Is New?

• This meta-analysis of 534 atrial tissue samples reveals a robust consensus transcriptional signature for atrial fibrillation (AF), identifying consistently dysregulated genes and pathways across heterogeneous patient populations and study designs.

What Are the Clinical Implications?

• The identified consensus signature provides a molecular framework for developing targeted diagnostic biomarkers and mechanism-based treatment strategies for AF, potentially leading to more personalized and effective management approaches.

• The study’s findings of conserved gene expression patterns across different AF types and the signature’s performance in classifying AF from peripheral blood samples suggest potential for non-invasive diagnostic and prognostic applications in clinical practice.

What New Question Does This Study Raise?

• Given the identified conserved molecular pathways in atrial fibrillation (AF), how do these transcriptional signatures evolve across different AF types (paroxysmal, persistent, and permanent) and in response to various therapeutic interventions?

What Question Should be Addressed Next?

• Can the consensus transcriptional signature be validated in large-scale, prospective studies to develop and evaluate blood-based biomarkers for early AF detection, risk stratification, and treatment response prediction?

• How do the identified dysregulated pathways, particularly those related to structural remodeling and metabolic reprogramming, interact with genetic predisposition and environmental factors to influence AF onset and progression?

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The development of this project was funded by the German Research Foundation (Collaborative Research Centre 1550, grant number #464424253 to SAGO, MVM, RO, FW, MK, CS, MF, and RTL), the Informatics for Life Initiative sponsored by the Klaus-Tschirra foundation (MM and RTL), the German Cardiac Society (Research Clinician-Scientist program to FW), the German Heart Foundation/German Foundation of Heart Research (F/03/19 to CS), and the Else-Kroner Fresenius Foundation (EKFS Fellowship and EKFS Clinician-Scientist professorship to CS). The funders had no role in study design, data collection, analysis, interpretation, or report preparation.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Bibliographic databases (MEDLINE/Ovid, EMBASE/Ovid, CINAHL/EBSCOhost, and Google Scholar) and data repositories (Gene Expression Omnibus database, the European Nucleotide Archive, ArrayExpress, and the European Genome Phenome Archive)

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes